This report provides an overview of the IT market for the life sciences industry. Analysis includes market size & growth, forecasts (up to 2020), demand drivers, adoption & scope trends, key areas of investment, and implications for key stakeholders. The report features two special sections – the first focuses on the market opportunity (for service providers) and the second focuses on buyer’s maturity of digital adoption (for enterprises).
Key findings of the report include:
Pharmatechnology and biotechnology are the most favorable opportunity segments
R&D and supply chain lines of business will drive a higher share of sourcing decisions
Application development and testing will witness fastest growth in services
More than two-thirds of the current digital investments are focused on growth
Contrary to popular belief, European pharma industry is ahead of United States in global digital investments
Analytics and cloud are the drivers behind most LS digital deals
Key strategic questions addressed in this report include:
For service providers:
What is the biggest opportunity segment in the global life sciences industry?
Which service line (applications, testing, workplace services, etc.) will be the growth driver?
What are buyers doing differently in their sourcing strategy?
How to stay relevant in a highly competitive market?
For enterprises:
How are peers in my segment investing in digital as an opportunity?
Is digital investment about growth, efficiency, or both?
Which value chain areas (R&D, clinical, supply chain, marketing, etc.) are garnering most investments from peers in the segment?
Who are the service providers that can deliver on integrated sourcing?
Note: this report is from 2012. See our most recent R2R research report.
The Finance & Accounting (F&A) function comprises three end-to-end processes – Procure-to-Pay (P2P), Order-to-Cash (O2C), and Record-to-Report (R2R). This report focuses on…